Introduction
In terms of therapy to treat infection, the antifungal drugs are the relative "new kid on the block." The polyenes were introduced in the 1950s and were the lone weapon in the arsenal until the 1990s when the first azole antifungal was introduced into clinical practice. The first echinocandin, Echinocandin B, was isolated in 1974 and was soon discovered to have antifungal properties [1] . However, the hemolytic properties of natural echinocandins prevented them from being viable candidates for human use, and it wasn't until the approval of the semisynthetic echinocandin, caspofungin, by the US Food and Drug Administration in 2001 that echinocandins were introduced into clinical practice.
Echinocandins, caspofungin, micafungin, and anidulafungin, act through noncompetitive inhibition of 1,3-β-D-glucan synthase, the enzyme responsible for the production of 1,3-β-Dglucan, a component of the cell wall in many species of fungus [2, 3] . The ability of an antifungal to target the cell wall is unique to echinocandins. The capacity is particularly desirable because of the absence of cell walls in animal cells, meaning a much lower risk of side effects caused by incidental action of the drug against the host's own cells, as with amphotericin B, which interacts with the sterols in human, as well as fungal, cell membranes. Additionally, their distinct mechanism of action allows echinocandins to be used against isolates that have already developed resistance to cell membrane-active antifungals. In Candida species, this disruption of the cell wall is fungicidal, leading to cell lysis via osmotic instability [3] .
Echinocandins are only effective against fungal species with cell walls that contain abundant 1,3-β-D-glucan, which precludes their use against Fusarium, the Mucormycetes, and Trichosporon. Although Cryptococcus species have 1,3-β-Dglucan, they remain resistant to the echinocandins [4] . In the USA and the European Union, this drug class is primarily approved for use against candidemia, esophageal candidiasis, and various forms of invasive candidiasis. Additionally, micafungin can be used as prophylaxis against Candida in hematopoietic stem cell transplant patients, and caspofungin is approved as treatment against invasive aspergillosis that is not responsive to other antifungals and for empiric treatment in febrile neutropenic patients.
Echinocandin Resistance
The primary mechanism of echinocandin resistance that has emerged since the introduction of the drug class into clinical practice is mutations in FKS1 and additionally in Candida glabrata, FKS2, genes that encode subunits of 1,3-β-D-glucan synthase. These mutations, first described in Candida isolates in 2005 [5] , occur in one of two areas, hot spot 1, located at amino acids 641-649 in Candida albicans [6] , and hot spot 2, located at amino acids 1345-1365 [7] . Hot spot mutations have been identified in C. albicans, C. glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida dubliniensis, and Candida guilliermondii [7, 8] . In two studies of C. glabrata, the presence of FKS mutations was significantly associated with treatment failure [9, 10] . The nature of the interaction between echinocandins and FKS1 has not been elucidated, so the mechanisms by which these substitutions lead to reduced susceptibility are unclear. It has been demonstrated, however, that substitutions at different amino acids, even within the same hot spots, can have different impacts on resistance profiles, in terms of which echinocandins are affected and the extent of the decrease in susceptibility [11, 12] . Furthermore, more than one of these mutations can occur in the same isolate, producing a less susceptible phenotype than would result from either mutation singularly [13, 12] .
Beyond FKS mutations, there are other mechanisms that have been suggested to cause resistance to echinocandins. One of these is the increase of cell wall chitin content to compensate for the 1,3-β-D-glucan depletion caused by echinocandin treatment. C. albicans has been demonstrated to have higher chitin content following in vitro treatment with echinocandins, as has C. tropicalis, some isolates of C. parapsilosis, C. guilliermondii, and, more rarely, C. krusei [14] . Increased chitin content was also found in a lab strain of C. glabrata treated with caspofungin [15] , but in a separate study, it was not found in several clinical C. glabrata strains grown with caspofungin at each isolate's IC 50 [14] . Multiple studies have correlated the induction of increased chitin content with decreased susceptibility to echinocandins in vitro and in vivo [14, 16] . However, these cells with induced high chitin content have also been shown to be less virulent and appear to be selected against in the absence of echinocandin [16] , raising doubts as to their clinical viability. Nonetheless, there has been at least one report of a patient infected with a caspofungin-resistant C. albicans isolate with chitin levels four times greater than those of a sensitive reference strain, in addition to an FKS1 hot spot 1 mutation [17] . While the extent to which the isolate's chitin levels contributed to its resistance is unclear, the case does demonstrate that it is possible for a strain with elevated chitin levels to cause a successful infection.
Interestingly, it has been suggested that increased chitin content may in fact precipitate FKS mutations. In a mouse model of infection, several isolates of a C. albicans strain that had been induced to possess increased chitin through growth with Ca 2+ and calcofluor white were found to possess FKS1 hot spot 1 mutations, even if the mice they infected had not been treated with echinocandins. In contrast, none of the normalchitin parental strains injected into mice contained any hot spot mutations [16] . It is possible that induction of the pathway that is responsible for increasing chitin content is also involved in increasing the likelihood of mutations in FKS1. At present, it is unclear what cellular changes allow some Candida species or strains within species to have a higher chitin content in the presence of echinocandins than others.
Finally, the intracellular buildup of long-chain bases dihydrosphingosine and phytosphingosine, both intermediates in the sphingolipid biosynthesis pathway, has been proposed as the mechanism of a caspofungin reduced susceptibility, micafungin increased susceptibility ("CRS-MIS"), profile observed in C. glabrata in both laboratory strains with induced caspofungin resistance and clinical strains [18, 19] . This phenotype was found to be induced by mutations to one of several enzymes involved in sphingolipid biosynthesis. The resulting excess of long-chain bases in the cell membrane has been hypothesized to alter the binding of echinocandins to Fks1p and Fks2p, weakening the interaction with caspofungin, while strengthening that with micafungin, based on the chemistry of the two echinocandins' tails [19] . While this CRS-MIS profile and its associated mutations have been observed in clinical isolates, there has been no research into whether the MIC effects are maintained in vivo. If they are, identifying isolates in which this phenomenon is active could inform patient treatment, preventing treatment escalation to amphotericin B for caspofungin-resistant isolates that would respond to micafungin.
There are several species of Candida that are of particular concern because of high in vitro MIC values to the echinocandins. C. parapsilosis has an intrinsic variation in its FKS sequence that coincides with a hot spot mutation [20] , and the mechanisms of Candida lusitaniae and C. guilliermondii may be similar [21, 22] . These appear to render them less susceptible to echinocandins in vitro, and the extent to which this affects the efficacy of clinical echinocandin treatment is not yet fully understood. While C. glabrata, does not possess intrinsic reduced susceptibility to echinocandins, it is also a species of concern for the development of drug resistance. Data suggest that rates of echinocandin resistance are greater in C. glabrata than in most other intrinsically susceptible species of Candida [23, 12, [24] [25] [26] and it has been hypothesized that C. glabrata's haploidy and genomic plasticity allows it to develop and strongly express resistance mechanisms more quickly than other Candida species [24, 12, 27] . This is particularly worrisome given that C. glabrata has reduced sensitivity to azoles, and now has echinocandins as its recommended first line treatment.
Epidemiology
Changes in the rates of echinocandin resistance are difficult both to ascertain and to interpret. One major problem in tracking the levels of echinocandin resistance and the temporal and geographic changes is that the available published data have been sorted according to several different sets of clinical breakpoints, including the current, species-specific Clinical and Laboratory Standards Institute (CLSI) breakpoints [28] , the 2008 CLSI breakpoints [29] , and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints [30] , none of which are directly comparable to one another. While CLSI and EUCAST antifungal susceptibility testing methods have generally shown high categorical agreement between wild-type and non-wild-type isolates as judged by epidemiological cutoff values for anidulafungin and micafungin when applied to the major Candida species [31] , it is unclear whether the same is true of susceptibility according to their respective breakpoints. Additionally, the fact that many publications describing rates of echinocandin resistance in the early to mid-2000s defined resistance according to the original, non-species-specific CLSI breakpoints has rendered much of this early data difficult to compare to current numbers, making it harder to determine how resistance to echinocandins has emerged since their introduction into practice. It should also be noted that while there are always questions as to the consistency of antifungal susceptibility results between testing sites, caspofungin MICs are notoriously variable, and there is some doubt as to whether they can be relied upon at all [32] .
Beyond the question of the consistency of antifungal susceptibility testing results and definitions from laboratory to laboratory and study to study, it is currently unclear how in vitro echinocandin resistance should be understood as an indicator of clinical resistance and treatment failure. The question lies in whether, as Alexander and coworkers [25] concluded after finding that every C. glabrata isolate with an echinocandin-resistant MIC that caused a treatment failure in their study also contained an FKS mutation, in vitro resistance "serve [s] as a sensitive but nonspecific phenotypic screen for the presence of clinically significant FKS mutations," or if elevated echinocandin MICs are independently predictive. The former theory was supported in one study where the only independent risk factor for echinocandin treatment failure against invasive C. glabrata was the presence of an FKS mutation [33] . However, another study of C. glabrata candidemia found that the caspofungin MIC was effective in predicting which FKS mutants would cause treatment failure, reaffirming the usefulness of in vitro susceptibility data as more than a proxy [34] . The same study identified prior echinocandin exposure, but neither MIC nor FKS mutations, as an independent risk factor for treatment failure, suggesting that there may indeed be other clinically relevant mechanisms of resistance that such exposure could be selecting for beyond just FKS mutations.
Rates of echinocandin resistance in Candida vary by species, region, institution, and patient population. Among C. albicans, resistance tends to be very low. SENTRY, a surveillance study including invasive Candida from North America, Europe, Latin America, and Asia-Pacific in 2010 and 2011, found resistant and intermediate rates in this species to be 0.0 and 0.4 % to anidulafungin, 0.2 and 0.4 % to caspofungin, and 0.1 and 0.3 % to micafungin, respectively [26] . In the USA, a study of candidemia from hospitals in Atlanta and Baltimore found 0.3 % resistance to anidulafungin, 0.5 % resistance to caspofungin, and 0.3 % resistance to micafungin [35] . C. parapsilosis also shows generally low levels of echinocandin resistance, with SEN-TRY capturing resistance rates of 0.5, 0.0, and 0.0 %, and Atlanta and Baltimore-based surveillance finding 0.0, 0.3, and 0.0 % to anidulafungin, caspofungin, and micafungin, respectively.
While still fairly low, the rates of resistance to C. glabrata are noticeably higher than those of the other Candida species. SENTRY surveillance in 2010 and 2011 found that rates of resistant and intermediate isolates were 1.8 and 4.6, 1.6 and 2.5, and 1.2 and 0.9 % for anidulafungin, caspofungin, and micafungin, respectively. These rates reveal considerable geographic variation, with no resistance in Latin America, equivalent resistance rates in Europe and North America (anidulafungin, 1.7 and 1.6 %, caspofungin, 1.7 and 1.6 %, and micafungin, 1.1 and 1.3 % in Europe and North America, respectively), and higher rates in Asia-Pacific (anidulafungin 3.8 %, caspofungin 1.9 %, and micafungin 1.9 %) [26] . The 2008-2011 candidemia surveillance in Atlanta and Baltimore captured 2.7, 2.4, and 2.7 % resistance to anidulafungin, caspofungin, and micafungin, respectively, with rates slightly higher in Atlanta than Baltimore (2.5-3.1 versus 2.3-2.5 % resistance to the three drugs). It should be noted that C. glabrata resistance rates in some individual institutions have been reported to be much higher, as with one eastern US hospital, which reported 12.5 % resistance to anidulafungin and micafungin and 13.5 % resistance to caspofungin in 2009 and 2010 [25] .
There is considerable evidence that exposure to echinocandins predisposes patients to developing echinocandin-resistant Candida. This has been identified as an independent predictor of the presence of an FKS mutation and echinocandin treatment failure in C. glabrata candidemia cases [34, 25] , and exposure to caspofungin within 30 days has been found to be an independent risk factor for blood stream infection with a Candida isolate with reduced caspofungin susceptibility in multiple studies [36, 37] . Epidemiological studies of drug resistance tend to include just the incident isolate of Candida infection. Many studies will not capture the isolates that develop echinocandin resistance over the course of treatment [35, 38] , isolates which have been described in multiple publications [39, 40] . It is therefore possible that current estimates of echinocandin resistance rates do not entirely encompass the population of patients affected by these reduced-susceptibility isolates.
There is evidence that rates of echinocandin resistance are rising, though the extent to which this is true seems to vary greatly by location. Several surveillance studies have compared past and recent rates of resistance, frequently revealing an upward drift over many years. This may be seen very slightly with C. albicans, as in one global surveillance study that found rates of nonsusceptibility (resistant+intermediate) go from <0.1, 0, and 0 % in 2003-2007 to 0.4, 0.6, and 0.4 % in 2010-2011 for anidulafungin, caspofungin, and micafungin, respectively [26] . However, it is found far more dramatically in C. glabrata, the nonsusceptibility rates of which climbed from 2.8, 1.5, and 0.9 % to 6.4, 4.1, and 2.1 % for the same drugs over the same time period [26] . A particularly extreme example of this is the study from the eastern US hospital cited above, which monitored C. glabrata echinocandin resistance from 2001 to 2010. During the first 6 years of the study period, resistance to each echinocandin ranged from~1.7 to~5.0 % during each 2-year period, after which it veered sharply upwards to~9.5-10.5 % for each drug in 2007-2008, and then~12.5-13.5 % in 2009-2010 [25] . Of course, there are also institutions and areas that do not seem to be experiencing the emergence of echinocandin resistance, as with a Spanish institution which found no echinocandin resistance in C. glabrata or C. parapsilosis from 2007 through 2013 (according to EUCAST antifungal testing methods and breakpoints) [41] or the Latin American laboratories contributing isolates to the global SENTRY surveillance program, which identified no C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, or C. krusei isolates resistant to anidulafungin or micafungin in 2008 and 2009 (isolates were not tested for susceptibility to caspofungin in this time range) [24] and no isolates of these species resistant to any of the echinocandins, with the exception of a single anidulafungin-resistant C. parapsilosis isolate among the 104 collected [26] .
The other factors contributing to the overall rise of echinocandin resistance among Candida isolates are the downward trend in relative C. albicans prevalence and corresponding upward trend in C. glabrata prevalence. This rise in C. glabrata has been noted by many studies [35, 42, 43, 38, 44] and has been attributed to widespread use of fluconazole, to which C. glabrata has intrinsically reduced susceptibility. Given that C. glabrata has shown itself more likely to develop echinocandin resistance, its increasing prevalence in the patient population increases the likelihood of a person with candidemia having a strain with reduced susceptibility.
There are several patient characteristics that have been found to predispose infecting Candida isolates to reduced echinocandin susceptibility. Not surprisingly, limited global surveillance has found nosocomial C. albicans and C. glabrata candidemia isolates to possess more echinocandin resistance than community-acquired isolates, though C. albicans resistance rates were still very low in nosocomial cases [45] . Resistance also seems to be associated with younger age, as global surveillance found the highest rates of C. glabrata echinocandin resistance in patients ages 20-39 (16.7 % to each echinocandin), followed by those ages 40-59 (7.0-4.2 %, by drug), with little to no resistance in the older age groups [46] . In this study, there were only five C. glabrata isolates from patients 0-19 years old, among which there was no resistance, but another study of Paris-area hospitals found being <15 years of age to be an independent risk factor for candidemia with reduced echinocandin susceptibility [37] .
Gastrointestinal (GI) disorders and recent GI surgery have both been significantly associated with infection with an isolate containing an FKS mutation. Each has also been associated with echinocandin treatment failure, the latter by univariate analysis only and the former by multivariate analysis [34, 33] . FKS mutations have also been found more frequently in solid organ transplant patients with C. glabrata candidemia [25] . Additionally, a French study found that patients with hematological malignancy were significantly more likely to have recent exposure to caspofungin, suggesting that they might also be at elevated risk for developing echinocandinresistant infections [37] . This conclusion is supported by the fact that half of FKS mutants collected by the French National Reference Center for Mycoses and Antifungals were from patients with hematological malignancy [40] . It is important to note that there is very little data on the medical conditions that predispose patients to developing echinocandin-resistant infections from broad surveillance studies, so much of this data comes from research specific to single institutions or regions. Knowing how widely antifungal prescribing practices can vary, it is unknown whether these findings are generalizable to a larger patient population.
Given that C. glabrata demonstrates an intrinsically reduced susceptibility to fluconazole, in addition to an apparent predisposition for the development of echinocandin resistance, there is a growing concern that multidrug-resistant C. glabrata will emerge as a considerable clinical problem. A study combining 2006-2010 SENTRY global surveillance and 2008-2010 CDC Atlanta and Baltimore-based surveillance from found that 9.7 % of C. glabrata isolates were resistant to fluconazole, and of these 11.1 % (accounting for 1.1 % of all C. glabrata) were resistant to at least one echinocandin, and all of these contained an FKS mutation [24] . When comparing this data to echinocandin resistance among fluconazole-resistant C. glabrata collected from 2001 to 2004, the authors saw a sharp increase, with resistance to each echinocandin going from 0 % in the first time period, to 8.0-9.3 % in the second time period. A study of C. glabrata candidemia isolates from four US cities found that 14.8 % of fluconazole-resistant isolates were resistant to at least one echinocandin, accounting for 1.5 % of all isolates [12] . In a study of C. glabrata candidemia isolates from 2001 to 2010, 14.1 % of fluconazole-resistant isolates were resistant to at least one echinocandin (3.5 % of all isolates), and 10.3 % were resistant to all three (2.5 % of all isolates) [25] . Interestingly, in this study, prior patient exposure to echinocandin therapy predicted not just echinocandin resistance, but also fluconazole resistance, most likely because echinocandin treatment was more frequently selected for patients who had already been exposed to fluconazole, or whose infective agent was suspected to have reduced susceptibility to this drug. Multidrug resistant profiles have also been found in other species of Candida, but these incidents are far less frequent, as with the single echinocandin and fluconazole-resistant C. albicans found in Baltimore between 2008 and 2011, accounting for 0.26 % of all of the city's C. albicans isolates [35] .
Conclusions
There are limited antifungal agents available to treat fungal infections. The development of resistance to echinocandins in Candida is a serious threat to our ability to manage these infections. Echinocandins are the empiric treatment of choice for candidemia, but it is essential that triazoles be used as soon as species or appropriate susceptibility of the Candida can be determined. This step down therapy is one important step in appropriate stewardship of this important antifungal agent. Although MDR Candida infections are still relatively uncommon, the emergence of these infections demonstrates the need for action now to improve stewardship and to continue to monitor for the development of resistance, as well as to study acquisition and transmission. It is imperative that we focus on antifungal resistance now before losing the ability to use these important drugs.
